Aleniglipron: an oral GLP-1 compound in phase 3

What is aleniglipron?

Aleniglipron, previously called GSBR-1290, is an investigational oral small-molecule agonist of the glucagon-like peptide-1 receptor. Structure Therapeutics is developing it for obesity and related metabolic disease. It acts at the same receptor targeted by GLP-1 medicines, but it is not a peptide. A shared biological target does not make two compounds chemically interchangeable.

The practical research question is whether a once-daily small molecule can deliver sustained weight reduction with tolerability that supports continued treatment. The ACCESS phase 2b trial provides a peer-reviewed answer over 36 weeks. The larger phase 3 programme is intended to test the approach in more participants and over a longer period.

What ACCESS actually measured

ACCESS was a randomized, double-blind, placebo-controlled phase 2b trial in 230 adults with overweight or obesity. Participants had a mean body mass index of 39.5 kg/m²; 54% were female. The study compared three aleniglipron target-dose groups with placebo over 36 weeks. The milligram values below identify trial arms, not instructions for use.

The primary efficacy analysis estimated weight change under a hypothetical scenario in which participants continued their assigned treatment. That is an efficacy estimand. It is useful for estimating drug effect, but it does not fully describe what happens when people stop treatment in everyday practice.

These are differences between aleniglipron and placebo, not the total percentage of starting weight lost in each active group. A placebo-adjusted difference of 11.3 percentage points should not be shortened to “participants lost 11.3%.” The distinction becomes especially important when comparing trials with different placebo responses.

The paper also reports a treatment-regimen analysis, which addresses the effect of treatment assignment regardless of whether participants remained on treatment. Neither analysis establishes how the drug compares directly with another active obesity medicine: ACCESS had a placebo control, not a semaglutide, tirzepatide or orforglipron arm.

A correction worth reading with the paper

Nature Medicine published a publisher correction on June 24, 2026. It changes the 120 mg label in Figure 3b from −12.1% to −12.7% and fixes missing elements in Figure 4. At our November 1 source check, the main article text and Figure 3a still displayed −12.1% for the highest-dose group, while Figure 3b displayed −12.7%.

We therefore use the consistently reported placebo-adjusted results above and do not quote a single total-weight-loss figure for that arm. The correction does not change the published −11.3 percentage-point placebo-adjusted estimate. Readers checking that result should read the paper and correction together rather than calculate a new estimate from the conflicting labels.^[2]

Tolerability is part of the result

Gastrointestinal adverse events were the main tolerability issue in ACCESS: nausea, diarrhoea, vomiting and constipation were commonly reported. Most were mild or moderate and occurred early in treatment. Across the active-treatment groups, 10.4% of participants discontinued because of treatment-related adverse events.

That discontinuation rate belongs alongside the efficacy result. A compound can produce a substantial effect in participants who remain on treatment while still presenting a practical challenge for those who cannot tolerate it. Dose escalation and retention are therefore central questions for the next studies.

No drug-induced liver injury was observed in ACCESS. This is reassuring within that study, but a 230-person trial cannot rule out uncommon harms or establish a long-term safety profile. Larger trials and longer follow-up are needed before stronger conclusions can be drawn.

What ACCESS II adds—and what it does not

A separate study, ACCESS II, investigated higher target doses over 44 weeks. In its March 16, 2026 topline announcement, Structure Therapeutics reported a maximum placebo-adjusted weight reduction of 16.3 percentage points under the efficacy estimand. The registered study enrolled 85 participants.^[3]

This result is a useful lead for understanding why the programme moved forward, but it has a different evidentiary status here: it comes from a sponsor announcement rather than the peer-reviewed ACCESS publication reviewed above. ACCESS II also had different treatment groups and a different follow-up period.

It should not be presented as an improvement from 11.3 to 16.3 within one continuous randomized comparison. Nor do the two results establish superiority to another oral GLP-1 candidate. A fair comparison would need to account for participants, titration, follow-up, missing data and the analysis used.

Phase 3: the ACCOMPLISH programme

Two registered phase 3 studies were recruiting at our November 1, 2026 check. Their records are the clearest guide to what comes next; they are not evidence that phase 3 efficacy or safety has already been established.

ACCOMPLISH-1 is registered as NCT07654361; ACCOMPLISH-2 as NCT07654374. Both records list estimated primary completion in September 2028. Planned enrolment and completion dates can change. A primary-completion estimate is not a promised results date or an expected approval date.^[4][5]

The diabetes population is particularly relevant to interpretation. Results from participants without diabetes cannot simply be assumed to apply at the same magnitude to people with type 2 diabetes. Separate studies can help clarify how weight, glycaemic outcomes and tolerability differ across those groups.

Why this compound is worth following

Aleniglipron offers a focused research story: an oral, nonpeptide GLP-1 receptor agonist with published phase 2b evidence and a registered phase 3 programme. The published data make it possible to examine its development beyond sponsor topline announcements.

The next useful evidence will show whether weight reduction persists, how many participants remain on treatment, and whether the safety findings hold in larger populations. Results from ACCOMPLISH-2 will also help assess the programme in people with type 2 diabetes. Full reporting of treatment discontinuation and both efficacy and treatment-regimen analyses will matter as much as the largest headline number.

For the wider context, see our oral obesity drug research overview, the orforglipron profile and the obesity drug pipeline timeline. Those articles describe neighbouring programmes; they do not provide head-to-head evidence against aleniglipron.